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Innovative strategies are needed to combat drug
resistance associated with methicillin-resistant
Staphylococcus aureus (MRSA). Here, we investigate
the potential of wall teichoic acid (WTA) biosynthesis
inhibitors as combination agents to restore b-lactam
efficacy against MRSA. Performing a whole-cell
pathway-based screen, we identified a series of
WTA inhibitors (WTAIs) targeting the WTA trans-
porter protein, TarG. Whole-genome sequencing of
WTAI-resistant isolates across two methicillin-resis-
tant Staphylococci spp. revealed TarG as their
common target, as well as a broad assortment of
drug-resistant bypass mutants mapping to earlier
steps of WTA biosynthesis. Extensive in vitro micro-
biological analysis and animal infection studies pro-
vide strong genetic and pharmacological evidence
of the potential effectiveness of WTAIs as anti-
MRSA b-lactam combination agents. This work
also highlights the emerging role of whole-genome
sequencing in antibiotic mode-of-action and resis-
tance studies.
INTRODUCTION
Staphylococcus aureus remains the leading cause of hospital
and community-acquired infections by Gram-positive bacteria
in much of the developed world (Boucher et al., 2009; Klevens
et al., 2007; Johnson, 2011). This is attributed in large part to
the emerging resistance of S. aureus to the entire armamen-
tarium of b-lactam antibiotics, a broad and historically important
class of antibiotics spanning penicillin, methicillin, and the more
powerful carbapenems, including imipenem, which kill bacteria
by inhibiting synthesis and chemical crosslinking of peptido-
glycan (PG), a cell wall polymer, leading to weakening of the
cell wall and cell lysis (Walsh, 2003).
The development of antibiotic combination agents has proven
to be a highly successful therapeutic strategy to combat drug
resistance, particularly against drug-resistant Gram-negative272 Chemistry & Biology 20, 272–284, February 21, 2013 ª2013 Elsebacteria (Drawz and Bonomo, 2010). Paramount to the rationale
of combination agents is the increased potency and efficacy
achieved by their combined effects. Ideally, this is achieved
by the synergistic bioactivity of both agents affecting two inter-
dependent cellular processes required for cell growth as well
as the targeted inactivation of the resistance mechanism to the
first agent by the combination agent (Tan et al., 2012). Applying
a systems biology approach to discovering synergistic agents
with this therapeutic potential is highly warranted; lethal or
even growth-crippling chemical genetic interactions highlight
a cellular network of interdependent biological processes and
potential drug targets from which combination agents may be
rationally discovered (Andrusiak et al., 2012; Costanzo et al.,
2010; Nichols et al., 2011). We and others have adopted this
approach to identify genetic mutations that restore b-lactam
activity against MRSA and as such predict that cognate inhibi-
tors of these b-lactam ‘‘potentiation’’ targets may similarly
restore the efficacy of the b-lactam (De Lencastre et al., 1999;
Berger-Ba¨chi and Rohrer, 2002, Huber et al., 2009; Lee et al.,
2011; Tan et al., 2012). Indeed, several cellular processes
contribute to buffering MRSA from the effects of b-lactams,
including normal synthesis of a second cell wall polymer, wall
teichoic acid (WTA) (Campbell et al., 2011; Lee et al., 2011). In
support of this notion, target-specific inhibitors of this process,
such as tunicamycin (Komatsuzawa et al., 1994; Campbell
et al., 2011), an exquisitely selective inhibitor of TarO, re-
sponsible for the first step in WTA synthesis (Swoboda et al.,
2009), was found to be highly synergistic in combination with
b-lactams.
WTA is a Gram-positive-specific anionic glycophosphate cell
wall polymer of roughly equal abundance to PG. Unlike PG,
however, WTA is not required for cell viability (Weidenmaier
et al., 2004; D’Elia et al., 2009b) but plays important roles in
cell growth, division, morphology, and as a virulence factor
(Schirner et al., 2009; Swoboda et al., 2010; Atilano et al.,
2010; Campbell et al., 2011; Dengler et al., 2012, Weidenmaier
and Peschel, 2008). WTA polymers are sequentially synthesized
on an undecaprenyl phosphate carrier lipid by a series of Tar en-
zymes localized on the inner face of the cytoplasmic membrane
before being exported to the cell surface by a two-component
ATP-binding cassette (ABC) transporter system and covalently
linked to PG (Brown et al., 2008; Swoboda et al., 2010; see
also Figure S1 available online). Interestingly, late steps in WTAvier Ltd All rights reserved
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for cell viability, whereas early steps (encoded by tarO/tagO
and tarA/tagA, respectively) are not (Weidenmaier et al., 2004;
D’Elia et al., 2006a, 2006b, 2009a, 2009b). Further, late-stage
WTA genes are in fact conditionally essential because they are
dispensable in either a tarO/tagO or tarA/tagA deletion back-
ground; this is referred to as the ‘‘essential gene paradox’’
(D’Elia et al., 2006a, 2006b, 2009b). Two hypotheses have
been given to explain these results: that toxic intermediate
WTA precursors accumulate in late-stage WTA mutants and/or
sequestration of the essential biosynthetic precursor, bactopre-
nol, occurs and this leads to depletion of PG because its
synthesis also requires bactoprenol as a carrier lipid (D’Elia
et al., 2006b, 2009b).
Walker and colleagues have recently exploited this phenom-
enon by screening for late-stage WTA inhibitors (WTAIs) that
phenocopy the genetic characterization of the pathway. Such
compounds should display intrinsic bioactivity against wild-
type S. aureus but lack activity against S. aureus strains in
which flux into the WTA pathway is abolished either by genetic
(e.g., tarO deletion) or pharmacological (e.g., tunicamycin)
means (Swoboda et al., 2009). One compound they identified,
1835F03, was subsequently optimized for potency and named
targocil (Lee et al., 2010; Suzuki et al., 2011). Drug resistance
mutant isolation revealed that targocil inhibits TarG, an essential
subunit of the WTA ABC transporter (Swoboda et al., 2009;
Schirner et al., 2011). As expected, resistance to targocil is
also achieved by loss-of-function mutations in tarO or tarA,
which effectively bypass the mechanism of action (MOA) of
targocil (Swoboda et al., 2009). Although the frequency of
resistance (FOR) to targocil is high (Lee et al., 2010), the contri-
bution of DtarO and DtarA mutants to targocil drug resistance
could be eliminated in the presence of oxacillin (Campbell
et al., 2011, 2012). Collectively, these findings suggest that
WTAIs could have significant potential as b-lactam combination
agents against MRSA.
Despite extensive genetic and pharmacological studies of
WTA biosynthesis in methicillin-sensitive S. aureus (MSSA)
strains, relatively little is known about this pathway in MRSA
strains in the context of a b-lactam potentiation target. Here,
we describe an analogous screening approach to identify and
characterize three additional classes of late-stage WTAIs that
inhibit TarG. We show that multiple TarG inhibitors also dis-
play broad antibacterial spectrum and markedly reduced FOR
in combination with imipenem. Interestingly, we demonstrate
that the clinically acquired MRSA strain COL has a much
broader repertoire of bypass mutations than previously identi-
fied. We show that these additional mutants are defective in
late-stage WTA biosynthesis and are attenuated in their viru-
lence in a murine deep thigh infection model. Further, all
mutants displayed striking hypersusceptibility phenotypes to
b-lactam antibiotics both in vitro and in an animal model of
MRSA infection, reinforcing the rationale for combining WTA
inhibitors with b-lactam antibiotics. Coadministration of TarG
inhibitors with imipenem displayed compound-specific syner-
gistic or strongly additive effects that approached standard
of care antibiotics and pharmacologically demonstrate the
potential of WTAIs as effective b-lactam combination agents
to treat MRSA.Chemistry & Biology 20, 272RESULTS
Pathway-Based Whole-Cell Screening for Late-Stage
WTAIs
As first demonstrated with targocil, small molecule inhibitors
of late-stage WTA enzymes are predicted to display intrinsic
growth inhibitory activity against S. aureus, which is specifically
reversed in a DtarO strain background (Swoboda et al., 2009).
Accordingly, a focused library of 20,000 S. aureus bioactive
synthetic compounds (Huber et al., 2009) was screened in tripli-
cate at two drug concentrations (3 and 16 mM) against the DtarO
and wild-type strains in tryptic soy broth (TSB) liquid medium in
a 1,536-well plate format with growth measured by optical
density. Compounds displaying greater than 80% reduced
activity against theDtarO strain versus wild-type were confirmed
provided they displayed distinct dose responses against the two
strains and an elevated minimum inhibitory concentration (MIC)
against DtarO strain versus wild-type (Figure 1). The confirmed
compounds, their physicochemical properties (see Table S1),
and chemical structures are shown (Figure 1A). Four compounds
(L275, L638, L541, and L640) are analogs of the tricyclic indole
structural class (note L541 and L640 follow-up was limited
because of compound availability and structural redundancy
with L275 and L638). L555 is a member of a large series of
N-aryl triazoles in which each member contains two chiral
centers, but only L555 displays bioactive chemotypes consistent
with inhibiting WTA biosynthesis (see Figure S2). The sixth
compound, L524, is structurally a member of C-aryl triazoles.
Interestingly, none of the compounds are structurally related to
targocil (see Table S1).
Microbiological Characterization of Late-Stage WTAIs
Based on extensive genetic characterization of WTA biosyn-
thesis in S. aureus, inhibitory compounds acting on late-stage
WTA assembly are predicted to phenocopy targocil and pheno-
types associated with loss-of-function mutations in late-stage
essential genes of the pathway (Swoboda et al., 2009). Accord-
ingly, MIC determinations of these compounds were determined
in comparison to targocil under a variety of conditions. Like tar-
gocil, each of the hit compounds displayed strong antimicrobial
activity, with MIC values ranging from 1–8 mg/ml against MSSA
strain RN4220 and MRSA strain COL, consistent with targeting
an essential cellular process, such as late-stageWTA biogenesis
(Figure 1B). Indeed, all compounds also display 4- to 32-fold
higher MIC values against DtarO or DtarA null strains, analogous
to genetic suppression of WTA late-stage essential gene muta-
tions in DtarO or DtarA strain backgrounds (D’Elia et al., 2006a,
2009a). S. aureus MIC values of each of these compounds
were also noticeably antagonized (4- to 16-fold) by the addition
of a sub-MIC level of tunicamycin (2 mg/ml) sufficient to specifi-
cally inhibit TarO activity (Campbell et al., 2011). Targocil is
also reported to have a bacteriostatic mode of action (Swoboda
et al., 2009; Campbell et al., 2012), and kill-curve analysis reveals
that L275, L638, L524, and L555 all strongly arrest S. aureus cell
division without compromising viability over an extended 24 hr
time course (see Figure S3). Therefore, each of the compounds
share striking microbiological characteristics with targocil that
are consistent with their role as inhibitors of late-stage WTA
biogenesis.–284, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 273
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Figure 1. Summary of WTAI Chemotypes
(A) Dose response growth curves of MSSA wild-
type strain RN4220 (blue) and DtarO (red) at
indicated drug concentrations for each putative
WTAI. Chemical structure and structural class are
indicated.
(B) Minimum inhibitory concentrations (MIC;
mg/ml) of WTAIs. Targocil bioactivity is included as
control and comparator compound. Tunicamycin
(Tuni) supplementation (2 mg/ml) is used to phe-
nocopy DtarO and DtarAmutants. Imipenem (IPM)
supplementation at 4 mg/ml reflects its clinical
break point concentration; highly reduced MIC
values under such conditions reflect synergy.
See also Figures S2, S3, and S5 and Tables S1
and S2.
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antisense interference-based depletion mutant of tarL (Lee
et al., 2011) displays highly specific b-lactam hypersusceptibility
phenotypes. Accordingly, we tested whether L275, L638,
L524, and L555 are synergistic in combination with imipenem
by scoring their fractional inhibitory concentration (FIC) index
(FICI) using the standard microdilution checkerboard assay,
where FIC indices of%0.5, 1–2, orR4 indicate synergistic, addi-
tive, or antagonistic chemical interactions, respectively (Amster-
dam, 2005). Each of the tested compounds tested against MRSA
COL produced FIC indices between 0.516 and 0.625, indicating
strong additivity in combination with imipenem (see Table S2).
Only L524 demonstrated a strong synergistic activity with imipe-
nem against methicillin-resistant Staphylococcus epidermidis
(MRSE; see Table S2).
To further examine whether L275, L638, L524, and L555 are
late-stageWTA inhibitors, L275was selected as a representative274 Chemistry & Biology 20, 272–284, February 21, 2013 ª2013 Elsevier Ltd All rights reservcompound to isolate drug-resistant
mutants using a recently described
S. aureus transposon (tsn) system
(Wang et al., 2011). Applying this
approach in MRSA COL, ten independent
tsn insertion mutants were identified,
each specifically inactivating tarO (n = 8)
or tarA (n = 2) (see Figure S4). These
loss-of-function mutations recapitulate
the demonstrated drug resistance com-
pensatory mechanism of targocil (Swo-
boda et al., 2009). Further, L275Rmutants
independently reproduce the initial
genetic basis that led to identification of
L275 and other compounds.
B. subtilis Expressing TarGH Is
Selectively Sensitized to L275,
L638, L524, and L555
Based on the observed phenocopy of
targocil treatment, we hypothesized that
our compounds may target the WTA
transporter, TarGH. To address this, we
determined compound MICs in both
a wild-type strain of B. subtilis and strainKS002, which is complemented with S. aureus TarGH in place
of native TagGH (Schirner et al., 2011).
The complemented strain KS002 displayed 4- R 32-fold
increased sensitivity to each of the compounds tested in com-
parison to wild-type B. subtilis, suggesting TarGH as the likely
target (see Figure S5). Activity against wild-type B. subtilis
also suggests an extended spectrum for these compounds in
comparison to targocil, which is specific for S. aureus (Swoboda
et al., 2009).
TargocilR Mutants Are Cross-Resistant to L275, L638,
L524, and L555
Fourteen independently derived targocil-resistant (targocilR; see
Table S3) mutants were isolated in MRSA COL, and those genes
previously implicated in drug resistance (tarO, tarA, and tarG;
Swoboda et al., 2009) were sequenced to identify causal muta-
tions. Such mutations provide an important resource to tested
Figure 2. Whole-Genome Sequencing of L275R and L638R Mutants
Heatmap summary of all nonsynonymous mutations identified by illumina-based whole-genome sequencing (100X genome coverage) of 20 independently
isolated L275R or L638R mutants in MRSA COL. Red, nonsynonymous mutation; black, no change versus parental MRSA COL genome sequence. Genome
position, base pair change, and resulting amino acid residue substitution are highlighted. Note: additional nonsynonymous mutations (yellow) mapping to
SACOL0539 (strains 707, 710, and 711) and SACCOL0687 (strain 663) are presumably unlinked to drug resistance as each strain also possesses a TarG amino
acid substitution. See also Figures S1, S4, and S7 and Tables S4 and S5.
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we identified. Expectedly, six targocilRmutantsmapped to either
tarO or tarA and contained either missense, nonsense, or inser-
tional loss-of-function mutations able to buffer the cell from the
effects of targocil (see Figure S6A). As expected, all DtarO and
DtarAmutants also exhibited a striking hypersusceptibility to imi-
penem with MIC values reduced 64- to 128-fold compared with
the wild-type MRSA COL strain. Importantly, eight additional
mutants mapped to TarG and correspond to the previously re-
ported targocilR TarG-W73C or TarG-M80I mutants (Swoboda
et al., 2009; Schirner et al., 2011), which despite conferring
a 4- to 8-fold level of resistance to targocil, similar to DtarO
and DtarA bypass mutants, lacked any change in their suscepti-
bility to imipenem, implying that these are not loss-of-function
mutations (see Figure S6A). Consistent with this view, TarG-
W73C and TarG-M80I mutants lack an obvious growth pheno-
type and produce WTA as inferred by their full susceptibility to
bacteriophage K-mediated cell lysis (see Figure S6B), which is
a process dependent on phage recognition of WTA polymers
that serve as a cell surface receptor for entry into the cell (Xia
et al., 2010).
Employing the above described targocilR mutant set, we
tested whether representative mutants are cross-resistant to
L275, L638, L524, or L555. Interestingly, TarG-W73C or TarG-
M80I MRSA COL strains are noticeably cross-resistant to each
of the four compounds tested (Table S3). Further, the extent
of cross-resistance observed was comparable to that of the
TarO-G48S loss-of-function mutant. As TarG-W73C and TarG-
M80I mutants appear to produce WTA (see Figure S6B), these
results strongly suggest that the tested compounds targetChemistry & Biology 20, 272TarG and that the suppression of their bioactivity is not due to
the absence of WTA polymers.
L275 and L638 Drug Resistance Mapping and
Mechanism of Action Studies
L275R and L638R mutant selection and next-generation whole-
genome sequencing (NGS) were performed in MRSA and
MRSE strain backgrounds. As expected, fast-growing L275R
and L638R MRSA COL strains contained an extensive set of
independently isolated TarG amino acid substitution mutations
(n = 20) (Figure 2). Indeed, several previously described targocilR
mutations, including TarG-F82L, TarG-C156Y, and TarG-Y190C
(Swoboda et al., 2009; Schirner et al., 2011), confer resistance
to L275 and/or L638. In addition, missense mutations yielding
amino acid substitutions at seven additional positions in the
TarG protein were identified. Many of these mutations map to
the same predicted transmembrane domains as previously
published targocilR mutations (Schirner et al., 2011; Figure 3A).
Additional TarG mutations map to the predicted extracellular
loop 1 (TarG-P64L) or extracellular loop 3 (TarG-H208Y, TarG-
Y217C) of the protein. As NGS analysis failed to identify any
additional nonsynonymous mutations beyond tarG in 80% of
L275R and L638R mutants examined, and in the remaining
instances in which a second nonsynonymous mutation was
detected a TarG amino acid substitution mutation was also
faithfully identified, we conclude that tarG mutations are causal
for the observed drug resistance. In only one instance (two
independently derived TarG-V54F mutations) was a growth
phenotype observed (see Figure S7). Interestingly, an alterna-
tive amino acid substitution at this residue (TarG-V54L) grew–284, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 275
Figure 3. Predicted Structural Topology of
TarG and Location of Drug Resistance
Amino Acid Substitutions
(A) Predicted topology of S. aureus TarG with
previously identified targocilR mutations (blue
diamonds), unique point mutations identified here
conferring L275R or L638R (red diamonds), and
resistance residues independently identified for
both targocil and L275 or L638 (purple diamonds).
Note: S. aureus and S. epidermidis TarG are 96%
homologous and share identical length (see Fig-
ure S8). Accordingly, S. epidermidis TarG L275R or
L638R mutations are also highlighted (boxed in
blue). TarG transmembrane topology was pre-
dicted using the SOSUI program and diagram
generated with TOPO2 software.
(B) WTA extraction and analysis of WTA levels in
MRSA COL challenged with 10X MIC of L638,
L555, L524 or control compounds Erythromycin
(Eryth), rifamicin (Rif), or Vancomycin (Vanc).
Tunicamycin (4 mg/ml; Tuni) treatment at subMIC
serves as a positive control for complete WTA
depletion.
See also Figure S1 and Tables S4 and S5.
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this mutation in effecting TarG function. Remarkably, all L275R
and L638R TarG mutations displayed a common cross-resis-
tance to L524, L555, and targocil but not to other antibiotic
classes tested (see Table S4).
Similarly, L275R and L638Rmutant selection and NGS analysis
performed in MRSE identified single nonsynonymous missense
mutations mapping to the S. epidermidis TarG protein. Indeed,
two of the drug-resistant mutations correspond to the same resi-
dues identified in S. aureus TarG (TarG-F82L and TarG-Y190H).276 Chemistry & Biology 20, 272–284, February 21, 2013 ª2013 Elsevier Ltd All rights reservAdditional mutations, TarG-S79I and four
independently derived mutations map-
ping to residue M211 (TarG-M211L and
TarG-M211I), are predicted to localize
within transmembrane 2 or extracellular
loop 3 domains, respectively (Figure 3A;
see also Figure S8). Collectively, these
studies provide strong genetic evidence
that TarG is the molecular target of
L275 and L638 across methicillin-resis-
tant Staphylococci and suggest that
they may interfere with TarG function by
binding either to the extracellular surface
and/or substrate channel of the WTA
transporter.
To further investigate inhibitory effects
on WTA biogenesis by our compounds,
WTA polymers were extracted from
drug-treated MRSA COL, normalized
according to cell biomass, and examined
by PAGE analysis (Meredith et al., 2008).
As L638, L524, and L555 are highly
potent and sufficient biomass is required
to isolate WTA from drug-treated cells,
high initial innocula (1 3 109 cells/drugtreatment) were required. WTA extracted from mock-treated
control cells appears as a ladder of discrete size polymers (Fig-
ure 3B). As expected, WTA biogenesis was completely abol-
ished by tunicamycin treatment and unaffected by antibiotic
controls. Conversely, L638 and L555-treated cells displayed
modest but reproducible changes in WTA polymer levels and/
or size (Figure 3B). L524-treated cells, however, exhibited only
a very minor decrease in WTA (as observed by reduced strain-
ing of higher molecular weight polymers), similar to repeated
attempts with targocil under identical conditions (data noted
Figure 4. L638R tar Mutants Share b-Lac-
tam Hypersusceptibility and WTA Depletion
Phenotypes
(A) Altered imipenem (IPM) susceptibility of MRSA
COL tar mutants by agar susceptibility assay (see
inset for description of specific mutations). Three-
fold serial dilutions of IPM (starting with 8 mg
material) spotted left to right across plate. Van-
comycin (Van; 2 mg starting material) serves as
control for specificity of b-lactam susceptibility
phenotype.
(B) Bacteriophage K resistance phenotype of
MRSA COL tar mutants.
(C) WTA extraction and PAGE analysis from L638R
MRSA COL tar mutants. Note: WTA material
normalized to cell biomass prior to loading.
See also Figure S9 and Tables S4, S5, and S11.
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test whether these compounds inhibit TarG directly, the incom-
plete depletion of WTA polymer levels by TarG inhibitors likely
reflects the fact that such agents effectively inhibit growth.
Consequently, pre-existing WTA comprising cells prior to TarG
inhibitor treatment is not diluted, as minimal cell doublings occur
postdrug treatment despite inhibition of new WTA biosynthesis,
whereas under tunicamycin subMIC conditions in which TarO-
mediated WTA biosynthesis of new material is specifically in-
hibited, cells robustly grow and dilute pre-existing WTA through
successive cell divisions.Chemistry & Biology 20, 272–284, February 21, 2013Extended NGS Analysis of L638R
Mutations in MRSA COL
NGS analysis was also performed with
a large number of slower growing MRSA
COL L638R mutants (n = 55) arising from
this study to confirm expected presence
of DtarO or DtarAmutations and examine
whether additional L638R compensa-
tory drug-resistance mechanisms exist.
Indeed, several L638R mutants mapped
to tarO or tarA and are presumed to
oblate gene function (Figure 4). However,
several additional mutants also mapped
to late-stage WTA genes, including tarB,
tarD, and tarI’ (Figure 4). Moreover, all
isolated tarB, tarD, and tarI’ mutants dis-
played similar phenotypes to DtarO and
DtarA mutants. In addition to their L638R
phenotype, tarB, tarD, and tarI’ mutants
displayed a striking cross-resistance to
targocil and other WTAIs (see Table S5),
as well as restoring susceptibility to
imipenem and prominent resistance to
phage K-mediated cell lysis, implying
they are also loss-of-function mutations
in these late-stage WTA genes (Figure 4).
Further, in numerous instances no
additional nonsynonymous mutations
beyond those associated with tar
genes were identified by NGS analysisof L638R mutants, thus ruling out the possibility that com-
pensatory mutations are responsible for the observed pheno-
types. To directly determine the severity of WTA phenotypes
associated with tarO, tarA, tarB, tarD, and tarI’ mutants, their
WTA was extracted and analyzed by PAGE. All mutants exam-
ined displayed dramatic alterations in WTA abundance and/or
polymer size (Figure 4C). Interestingly, these results demon-
strate that MRSA COL is able to tolerate profound loss-of-
function mutations in late-stage WTA biosynthesis genes and
that such mutations expand its repertoire of resistance to TarG
inhibitors.ª2013 Elsevier Ltd All rights reserved 277
Figure 5. Conditional Essentiality of MRSA
COL tar Mutants
Growth phenotype of MRSA COL tar mutants
spotted as 3-fold serial dilutions starting at 53 104
cells/spot (left to right) on LB medium, LB + 4%
NaCl, LB + 7.5% NaCl, and +/ tunicamycin
(2 mg/ml) supplementation grown at 37C or
42C for 18 hr. See also Figure S6 and Tables S3
and S11.
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Osmotic-Sensitive Growth Phenotypes
Identifying viable mutations in late-stage WTA genes with dra-
matic loss-of-function phenotypes was not expected because
they were shown to be essential in both S. aureus and
B. subtilis (D’Elia et al., 2006a, 2006b). To reconcile these find-
ings, tarB, tarD, and tarI’ mutant phenotypes were compared
to DtarO and DtarA mutants under conditions of elevated
temperature and osmotic stress. tarB and tarD mutants grown
on LB agar displayed modest growth phenotypes at 37C, and
all tar loss-of-function mutants tested exhibited marked growth
phenotypes under high osmotic pressure with 7.5% NaCl
(Figure 5). Consistent with the expectation that these pheno-
types are linked to the tar mutation, supplementing the medium
with 2 mg/ml tunicamycin partially reversed their observed
phenotypes. tarB, tarD, and tarI’mutants also displayed striking
temperature-sensitive growth phenotypes at 42C, whereas tarA
and tarOmutants shared only mild growth phenotypes, as previ-
ously reported (D’Elia et al., 2006a, 2009a). Thus, the relative
severity of tarmutant growth phenotypes mirror that determined
in a MSSA RN4220 strain background but is observed at higher
temperature in MRSA COL. All temperature-sensitive growth
phenotypes were noticeably suppressed by tunicamycin or 4%
NaCl supplementation and fully suppressed by adding both tuni-
camycin and 4% NaCl (Figure 5). Further, at 37C under hypo-
tonic growth conditions (no NaCl in Luria broth [LB] medium),
tarB and tarD mutants are also growth impaired and fully sup-
pressed by cosupplementing tunicamycin and 4% NaCl (see
Figure S9). At 42C under hypotonic conditions, all tar mutants
(including tarO and tarA mutants) displayed extreme growth
phenotypes fully reversed by tunicamycin and 4%NaCl (see Fig-
ure S9). These results corroborate the temperature-sensitive and
osmotic remedial growth phenotypes of DtarO mutants (Hoover278 Chemistry & Biology 20, 272–284, February 21, 2013 ª2013 Elsevier Ltd All rights reservand Gray, 1977; Vergara-Irigaray et al.,
2008) and extend these finding to tarA
as well as tarB, tarD, and tarI’ loss-of-
function mutants. Therefore, relatively
minor differences in growth conditions
can profoundly impact the viability of
S. aureus strains defective in late-stage
WTA biosynthesis.
Attenuated Virulence Phenotypes
of MRSA COL Strains Defective in
Early- or Late-Stage WTA
Biogenesis
Identifying L275R and L638R loss-of-
function mutants that map to early andlate-stage WTA biosynthetic genes enabled us to examine their
possible virulence phenotypes in MRSA COL using a previously
described murine thigh infection model (Gill et al., 2007). We
reasoned that in vivo phenotypes may well be expected based
on results obtained from extensive in vivo studies using MSSA-
derived tarO mutants (Weidenmaier et al., 2004, 2005; Weiden-
maier and Peschel, 2008). Moreover, temperature and osmotic
stress growth phenotypes of MRSA COL tarB, tarD, and tarI’
mutants we observed under laboratory growth conditions may
decrease S. aureus pathogenicity. As expected, tarO and tarA
mutants typically displayed an approximate 1 log reduction in
bacterial burden after 24 hr versus the wild-type parental strain
over a broad range of infection doses in this animal model (Fig-
ure 6A; Table S6). Interestingly, at the lowest infection dose
used (1 3 106 cells), the tarO mutant strain displayed an even
more pronounced attenuated virulence, nearing as much as
a 4 log reduction in bacterial burden compared to wild-type
MRSA COL. Similarly, tarD and tarI’ mutants also displayed
dramatic attenuated virulence phenotypes, particularly across
lower infection doses, where as much as 3 log reductions in
bacterial burden were observed, whereas the tarB mutant
more closely mirrored the tarA with bacterial burden after 24 hr
reproducibly reduced 1 log across all infection doses tested.
These data demonstrate the relevance of WTA as a virulence
determinant in S. aureus and suggest that their attenuated viru-
lence phenotypes may further reduce the threat of drug resis-
tance in a therapeutic context.
Imipenem Efficacy against MRSA tar Mutants Resistant
to TarG Inhibitors
As tarO, tarA, tarB, tarD, and tarI’ loss-of-function mutations en-
hance MRSA COL susceptibility to b-lactam antibiotics in vitro,
we tested whether this phenotype extends to the deep thighed
AB
Figure 6. Attenuated Virulence and Imipenem Hypersusceptibility of
MRSA COL tar Mutants in a Murine Deep Thigh Infection Model
(A) Attenuated virulence of tarmutants versusMRSACOLwild-type (black line)
across 4 log escalation in infection dose. See inset for description and color-
coding of specific mutants. Infection inocula of M14 (TarO-Y95stop) strain was
one log great than other strains tested. Two hour (106) bacterial burden control
confirms infection dose (106/thigh) when enumerated from animals 2 hr
postinfection. See also Table S6.
(B) Restored efficacy of Imipenem against MRSA COL tar mutants. Immune-
suppressed CD-1 mice (five mice per group) were challenged intramuscularly
with 1 3 106 cfu/thigh of MRSA COL or the indicated MRSA COL tar mutant.
Imipenem (IPM; 10 mg/kg) or vehicle (Veh; 10 mM MOPS) were dosed
subcutaneously (s.c.) three times over a 24 hr period. Thigh homogenates were
obtained 2 hr postinfection and prior to treatment (Pre), or post-24-hr treat-
ment with Veh or IPM and serially plated to determine cfu/thigh remaining.
Bacterial burden was enumerated and compared among three groups. *p <
0.05 versus respective 2 hr control; f p < 0.05 versus respective 24 hr control.
See also Table S7.
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MRSA-COL-infected animals in this model when dosed at
10 mg/kg subcutaneously three times a day (tid) for 24 hr versus
the mock-treated control group administered 10 mM MOPS as
vehicle (Figure 6B). However, imipenem efficacy was restored
in mice infected with tarO, tarA, tarB, or tarD mutant strains,Chemistry & Biology 20, 272producing an 3 log reduction in bacterial burden versus the
parental COL strain identically treated with imipenem (Figure 6B;
Table S7). Similarly, imipenem treatment achieved an 2 log
reduction in bacterial burden with mice infected with a tarI’-defi-
cient strain versus wild-type COL. Therefore, we expect that the
drug resistance to TarG inhibitors, mediated by the selection for
these compensatory bypass mutants will be reduced in an
MRSA infection setting by combining such agents with a b-lac-
tam antibiotic. These data also provide clear genetic demonstra-
tion that in addition to TarO and TarA, late-stage WTA enzymes,
including TarB, TarD, or TarI’, are also therapeutically relevant
MRSA b-lactam potentiation targets.
TarG Inhibitors ± Imipenem Frequency of Resistance
Targocil displays a high FOR of 7 3 107 cells at 8X MIC (Lee
et al., 2010), which is substantially reduced in the presence of
the b-lactam, oxacillin (Campbell et al., 2011). Accordingly, we
examined the spontaneous rate of drug-resistant mutants iso-
lated among this extended set of TarG inhibitors. L524 and
L555 displayed markedly higher or marginally lower FOR than
targocil, respectively, over a range of MIC levels tested (Table
1). Whereas L638 tested at 2X MIC or 4X MIC only minimally
reduced FOR (2 3 107) compared to targocil, a borderline-
acceptable FOR of 1.93 108 was achieved at 8XMIC. Interest-
ingly, L275 displayed a highly favorable dose-dependent
FOR, with spontaneous drug-resistant isolates recovered at a
frequency of 4 3 108 at 2–4 X MIC, and %3.6 3 1010 at
6–8XMIC levels (Table 1). Further, in combination with imipenem
at a subMIC level of 4 mg/ml (its clinical break point concentration
againstMRSA; Tan et al., 2012), similar L275 FOR levels could be
achieved at as low as 2X its MIC. Remarkably, resistance asso-
ciated with L275 in combination with a subinhibitory concen-
tration of imipenem was therefore reduced 104-fold from the
original FOR of targocil.
TarG Inhibitors ± Imipenem In Vivo Efficacy
TarG inhibitors display favorable in vitro potency but possess
high plasma protein binding, which could diminish their efficacy
in a treatment model of MRSA infection (see Table S8). As this
issue may be particularly problematic if the site of infection is
muscle tissue, such as the deep thigh infection model, we turned
to an alternative animal efficacy model involving an intraperito-
neal challenge and subsequent kidney colonization by MRSA
COL (Gill et al., 2007). Targocil, L275, L638, or L555 administered
subcutaneously at 200 mg/kg tid did not significantly reduce
bacterial burden after 24 hr treatment, as measured by colony-
forming units per gram kidney tissues (cfu/g) versus vehicle-
control-treated animals (Figure 7; see also Table S9). Further,
imipenem singly administered subcutaneously at 10 mg/kg tid
in this animal model only modestly reduced bacterial burden
by 1.5 log cfu/g versus vehicle control group. However, a
strongly additive or synergistic efficacy was achieved by coad-
ministering TarG inhibitors with a subefficacious treatment of
imipenem. For example, coadministering TarG inhibitors subcu-
taneous at 200 mg/kg tid and imipenem administration markedly
reduced bacterial burden among treatment groups ranging from
2-3 log cfu/g versus vehicle control group. Although only L275
displayed significant synergy in combination with imipenem
versus imipenem alone (t test p < 0.05), coadministering these–284, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 279
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bacterial burden to levels achieved by linezolid or ciprofloxacin
treatment.
DISCUSSION
Applying a chemical biology screen designed to mimic the well-
characterized WTA gene dispensability phenotypes in S. aureus,
we identify a series of synthetic compounds each chemically
distinct from targocil. Extensive drug resistance mapping
studies performed inMRSA andMRSE provide genetic evidence
that like targocil, small molecules we report here inhibit TarG as
their primary drug target. Corroborating this conclusion, WTA
levels are partially depleted in TarG inhibitor-treated cells, partic-
ularly L638 and L555 structural classes, and bypassmutations to
these WTAIs correspond to loss-of-function mutations in tar
genes that function upstream of TarG. Depending on their struc-
tural class, TarG inhibitors described here display either the
selectivity and propensity for resistance as targocil or an
improved antibacterial spectrum and markedly reduced fre-
quency of drug resistance. As drug-resistant bypass mutations
isolated in MRSA COL are dramatically hypersensitive to
b-lactam antibiotics, the effective FOR of these compounds
can be dramatically reduced in combination with subinhibitory
concentrations of imipenem. These studies suggest TarG to be
a highly druggable antibacterial target and demonstrate that
cognate inhibitors display in vivo efficacy when paired with
imipenem in treating an animal MRSA infection.
Essential versus Conditional Essential Phenotypes
of Late-Stage WTA Biosynthetic Genes
Two hypotheses for the reported essentiality of late-stage WTA
biosynthetic genes and nonessentiality of early-stage WTA
genes have been widely considered (D’Elia et al., 2006a,
2006b, 2009c). Specifically, loss-of-function mutations in late-
stage WTA genes may accumulate toxic WTA intermediates
and/or decrease available bactoprenol necessary for peptido-
glycan synthesis to growth impairing levels. So, why do multiple
late-stage WTA genes appear nonessential in MRSA COL when
they have been demonstrated to be essential in MSSA strain
RN4220? MRSA COL may simply produce more bactoprenol
or possess greater flexibility in recycling bactoprenol from the
WTA intermediates than S. aureus RN4220 or B. subtilis strains
in which the terminal phenotype of WTA mutations have been
examined (D’Elia et al., 2006a, 2006b). Alternatively, tarB, tarD,
and tarI’mutants isolated heremay be viable because they retain
some minor level of residual activity that is required to reverse
bactoprenol flux and such an activity would be absent among
null mutations, rendering the latter inviable. Accordingly, the
fact that such mutants make little to no WTA does not impair
viability but some minimal level of WTA biosynthesis may be
necessary to recycle bactoprenol. We also note that our tar
mutant phenotypes are derived from amino acid substitution or
C-terminal truncation mutations, all of which in the context of
a postulated multimeric WTA enzyme complex (Formstone
et al., 2008) may produce less severe phenotypes than com-
plete gene deletion mutations. Importantly, MRSA COL muta-
tions in late-stage WTA biosynthesis are in fact conditionally
essential at 42C. Moreover, consistent with S. aureus WTAvier Ltd All rights reserved
Figure 7. TarG inhibitors Augment Imipenem Efficacy
Immune-suppressed Balb/c mice (five mice per group) were challenged
intraperitoneally with23 104 cfu of MRSA COL and dosed s.c. with the WTA
inhibitor (200 mg/kg), imipenem (IPM; 10 mg/kg) coformulated with 50 mg/kg
cilastatin, or coadministration of the TarG inhibitor and imipenem/cilistatin at
2, 5, and 8 hr postinfection challenge. Kidneys were aseptically collected,
homogenized, and plated 24 hr after challenge to determine cfu remaining per
gram kidney tissue. Linezolid (Lin; 10 mg/kg dosed orally) and ciprofloxacin
(Cip; 12.5 mg/kg dosed s.c.) serve as positive control antibiotics for demon-
strating efficacy. #, significant (p < 0.05) versus vehicle; $, significant (p < 0.05)
versus IPM alone; A, significant (p < 0.05) versus IPM alone. See also Tables
S8 and S9.
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tarB, tarD, and tarI’ mutant phenotypes were noticeably sup-
pressed by supplementing tunicamycin at levels that phenocopy
deletion of tarO. Therefore, we conclude that the paradoxical
severity of growth phenotypes among mutants in early versus
late-stage WTA synthesis is conserved in MRSA COL. However,
the absolute strength of these phenotypes can vary contextually
in different S. aureus genetic backgrounds as might be expected
considering the extensive genomic diversity identified among
multiple fully sequenced S. aureus strains (Feng et al., 2008).
Off-Target Activity of L275, L638, L640, and L555
Unlike targocil, which is a highly specific inhibitor of S. aureus
TarG activity (Swoboda et al., 2009; Schirner et al., 2011), several
of the compounds we have identified likely possess an off-target
activity. First, bioactivity of each of the new TarG inhibitors (with
the exception of L524) is not fully suppressed by genetic or
chemical inhibition of TarO. Second, these TarG inhibitors
display a notable antibacterial activity that exceeds the spec-
trum of bacteria possessing a TarG ortholog orWTA biosynthetic
pathway, including Streptococcus pyogenes as well as Gram-
negative bacteria, including Moraxella catarrhalis and Haemo-
philus influenzae (see Table S10). Finally, L275, L638, and L555
display dramatically lower FOR against MRSA COL compared
to targocil over a range of drug concentrations assessed either
singly or in combinationwith imipenem. As all resistancemutants
to these compounds isolated in both MRSA and MRSE sharedChemistry & Biology 20, 272either a TarG or the WTA bypass-mediated mechanism of
resistance and these compounds lack anti-Candida albicans
activity, we favor that this off-target activity reflects a secondary
target rather than nonspecific/general cellular toxicity of the
compounds. Studies to identify a potential secondary target to
these compounds are ongoing.
TarG Is a Highly Druggable Target
Despite the opportunity for this pathway-based screen to iden-
tify inhibitors to any of the late-stage WTA enzymes, only TarG
WTAIs have been reported by us and prior work (Swoboda
et al., 2009). Interestingly, these inhibitors represent structurally
distinct chemical series. We speculate that TarG is a particularly
‘‘druggable’’ target when compared to other Tar enzymes. The
S. aureus WTA transporter is predicted to be a heteromeric
complex consisting of dimers of the cytoplasmic ATPase subunit
TarH and a WTA substrate channel forming subunit, TarG
(Cuthbertson et al., 2010; Schirner et al., 2011). Therefore,
TarG is uniquely exposed to the extracellular milieu and poten-
tially susceptible to inhibitors that need not enter the cytoplasm.
Consistent with this, all drug-resistant mutations to WTAIs we
describe map to the presumed substrate channel or extracellular
domains of TarG. Considering the substantial size of the
substrate channel required to translocate WTA across the
plasma membrane, structurally diverse compounds may have
access to the channel and sterically interfere withWTA precursor
export. In such a manner, TarG inhibitors would be mechanisti-
cally analogous to diverse protein synthesis inhibitors, which
bind to the ribosome polypeptide export tunnel to block release
of nascent polypeptides (Walsh, 2003).
WTAIs as b-Lactam Combination Agents
Significant therapeutic advantages are anticipated by combining
a WTAI with existing b-lactam antibiotics to treat MRSA infec-
tions. These include improved antibacterial potency by the
strong additivity or synergistic activity of the two agents and
reduced drug resistance in the context as dual agents. Unex-
pectedly, the degree of observed synergy between imipenem
and TarG inhibitors is generally lower than genetic analysis
would predict. Campbell et al. (2012) have suggested that this
may reflect the fact that b-lactams are only effective against
actively growing cells and the bacteriostatic nature of TarG inhib-
itors might antagonize b-lactam activity. Conflicting with this
view, however, is the fact that b-lactams suppress the FOR of
TarG inhibitors. Alternatively, the lack of striking in vitro synergy
between these agents may reflect a limitation in the sensitivity of
the standard microdilution checkerboard assay (Amsterdam,
2005), particularly when testing potent bioactive agents.
Whereas the checkerboard assay effectively scores synergy
between nonbioactive agents, synergistic effects between
bioactive agents may occur rapidly and possibly over only
a few cell division cycles, obscuring such chemical-chemical
interactions. Regardless, we demonstrate that their combined
effects are pronounced in an animal model of MRSA infection.
This exaggerated efficacy in a host environment reflects the
dualmanner in which these agents impair normalWTA synthesis,
hence depleting an important S. aureus virulence determinant
(Weidenmaier et al., 2004; Weidenmaier and Peschel, 2008)
and therefore disrupting the integrity of the cell wall to potentially–284, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 281
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determinants required to activate an innate immune response
(Guan and Mariuzza, 2007; Pietrocola et al., 2011).
Importantly, reduced drug resistance is achieved by
combining TarG inhibitors with imipenem, as recently demon-
strated with targocil and oxicillin (Campbell et al., 2012) as well
as a second b-lactam synergistic combination involving the
FtsZ inhibitor, PC190723, and imipenem (Tan et al., 2012).
Remarkably, L275 at 2X MIC combined with the break point
concentration of imipenem reduces the FOR of the combined
agents to extremely low levels. This can likely be attributed to
strong counterselection of bypass resistance mutants in the
presence of the b-lactam due to their dramatic hypersensitivity
to imipenem and the impact of L275 secondary target activity,
particularly at higher drug concentrations.
Chemical Biology, Drug Resistance Analysis,
and Whole-Genome Sequencing
We demonstrate that combining a robust whole-cell-based
screen to identify pathway-specific bioactive compounds with
drug resistance selection andNGS technologyprovides apower-
ful strategy to successfully identify target-specific inhibitors,
their MOA, and drug resistance mechanisms and to genetically
predict the pharmacological effects of such agents. Drug-resis-
tant mutants identified in this study also provided a valuable
resource to genetically validate other genes in the WTA pathway
as new b-lactam potentiation targets. Further, the resulting
mutations were valuable reagents to verify that genetic depletion
of tarO, tarA, tarB, tarD, or tarI’ inMRSA producemarkedly atten-
uated virulence and b-lactam hypersusceptibility phenotypes in
a host setting. Accordingly, the strategy can be used to draw
strong target validation conclusions. Chemical biology studies
on the effects of these compounds themselves provided a
‘‘surrogate’’ genetic strategy to chemically select for a broad
set of WTA pathway mutants, therefore bypassing molecular
genetic methodologies necessary to evaluate such targets. We
believe that combining resistance, suppression, or other selec-
tion studies with NGS-based mapping of causal mutations will
have an extraordinary impact, not only in antimicrobial discovery
but broadly in the fundamental pursuit of linking chemistry and
biology.
SIGNIFICANCE
Innovative strategies to combat drug resistance associated
with methicillin-resistant Staphylococcus aureus (MRSA)
and other b-lactam-resistant Staphylococci are needed.
Here, we have investigated the potential of wall teichoic
acid (WTA) inhibitors as combination agents to effectively
restore b-lactam susceptibility and reduce drug resistance
among pre-existing drug-resistant Staphylococci. Perform-
ing a whole-cell pathway-based screen for WTA inhibitors
(WTAIs), we identified three potent and structurally distinct
classes of bacteriostatic agents with extended Gram-
positive spectrum targeting TarG, the channel forming
subunit of the WTA transporter. We use whole-genome
sequencing analysis in MRSA as well as in methicillin-
resistant Staphylococcus epidermidis (MRSE) to map the
drug resistance landscape. These analyses cross-validate282 Chemistry & Biology 20, 272–284, February 21, 2013 ª2013 Elsea TarG-mediated mechanism of action for each of these
WTAIs. Multiple drug-resistant loss-of-function bypass
mutations in earlier steps of WTA biosynthesis were also
recovered, including tarO and tarA, as well as tarB, tarD,
and tarI’, the latter of which are essential for growth in the
methicillin-sensitive Staphylococcus aureus (MSSA) strain
backgroundRN4220 but notMRSACOL. Phenotypic charac-
terization of tar mutants reveals their attenuated virulence
and profound hypersusceptibility to b-lactam antibiotics in
amurine infection model. Pharmacological evidence of their
b-lactam potentiation activity is also achieved in an in vivo
infection setting. Thus, genetic and pharmacological studies
demonstrate the potential of WTAIs as effective b-lactam
combination agents to treatMRSA. Thiswork also highlights
the incredible robustness and efficiency of combining clas-
sical drug resistance selection andwhole-genome sequenc-
ing to identify drug targets and impact small molecule MOA
and resistance studies.
EXPERIMENTAL PROCEDURES
Microbiological Studies
MRSA COL is a hospital-acquired penicillinase-negative strain extensively
used in Staphylococcus aureus methicillin resistance and virulence studies
(De Lencastre et al., 1999; Tan et al., 2012) and from which its genome
has been fully sequenced and annotated (Gill et al., 2005). MRSE strain
(MB6255) is a previously described methicillin-resistant S. epidermidis clinical
isolate (CLB26329; Huber et al., 2009) isolated from a New York intensive care
unit in 2004. MICs were determined by the broth microdilution method in
accordance with the recommendations of the Clinical and Laboratory
Standards Institute. The standard checkerboard technique was used to quan-
tify synergy between antibiotic agents (Amsterdam, 2005). MRSA COL and
MRSE MB6255 were grown in cation-adjusted Mueller Hinton broth (CAMHB)
medium and assayed in a 96-well format using 2-fold dilutions of imipenem
and TarG inhibitors. MIC determinations were assessed visually. FICI values
were determined by adding the FIC value of each compound required to
achieve a MIC when paired with the second agent. Bacteriophage K cell lysis
assays (Swoboda et al., 2009; Xia et al., 2010), transposon-mediated selection
of L275 drug-resistant mutants (Wang et al., 2011), WTA extraction analyses
(Meredith et al., 2008), and time kill studies (Tan et al., 2012) were performed
as previously described. An agar susceptibility assay was performed as previ-
ously described (Lee et al., 2011).
Isolation of MRSA COL TargocilR, L275R, and L638R Mutants
MRSA and MRSE strains were grown to late-exponential phase (OD600 1.0;
approximately 109 cfu/ml) and spread on BHIA plates containing 2-fold esca-
lating agar MIC levels of TarG inhibitors. To establish the number of viable cells
in the starting inoculum, the culture was serially diluted and plated on BHIA
plates lacking the TarG inhibitor. Resistant isolates were restreaked on plates
containing the same TarG inhibitor concentration. The frequency of resistance
(FOR) either in the absence or presence of 4 mg/ml imipenem was determined,
dividing the number of resistant isolates by the viable cfu in the late-exponen-
tial inoculum. See Table S11 for detailed description of mutants.
TarG Inhibitor Efficacy Studies
Efficacy studies were performed using a previously described murine septi-
cemia model of S. aureus infection, where immune-suppressed Balb/c mice
(five mice per group) were challenged with 1.8 3 104 cfu MRSA COL in 3%
hog gastic mucin (Gill et al., 2007). Mice were dosed subcutaneously (s.c.)
with the WTA inhibitor (200 mg/kg), imipenem (IPM; 10 mg/kg) coformulated
with 50 mg/kg cilastatin, or coadministration of the TarG inhibitor and imipe-
nem/cilistatin at 2, 5, and 8 hr postinfection challenge. Kidney homogenates
were serially plated 24 hr after initiation of therapy to determine cfu/kidney
remaining. Pharmacokinetic and plasma protein binding properties of TarG
inhibitors are provided in Table S8. All animal experiments were performedvier Ltd All rights reserved
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of animals.
In Vivo Virulence Studies of MRSA COL tar Mutants
Virulence phenotypes were assessed using a previously described murine
deep thigh infection model (Gill et al., 2007; Tan et al., 2012). Bacterial cultures
of MRSA COL (MB 5393), tarO, tarA, tarB, tarD, and tarI’ were grown in TSB
medium overnight to late-exponential phase (OD600 1.0; approximately
109 cfu/ml). Five groups of mice were thigh inoculated (0.1 ml/injection)
with an isolate, each at increasing inoculum concentrations ranging from
105–109 cfu/ml. Thigh homogenates were serially plated 24 hr after infection
to determine cfu/thigh remaining.
Restored Efficacy of Imipenem against MRSA COL tar Mutants
Imipenem efficacy studies were performed using a previously described
murine deep thigh infection model (Gill et al., 2007; Tan et al., 2012). Female
CD-1 mice inoculated into the thighs with overnight cultures (106 cfu/thigh)
of MRSA COL, or representative tar mutants were treated with vehicle or imi-
penem (10 mg/kg per dose 3 3 over 24 hr). Thigh homogenates were serially
plated after 2 or 24 hr (vehicle, imipenem) to determine cfu/thigh remaining.
SUPPLEMENTAL INFORMATION
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